Navigation Links
Anadys Pharmaceuticals Reports Third Quarter 2008 Financial Results and Highlights
Date:10/23/2008

elephone replay will be available through November 6, 2008.

About Anadys

Anadys Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company dedicated to improving patient care by developing novel medicines in the areas of hepatitis C and oncology. For the treatment of chronic hepatitis C, the Company is developing two potentially complementary agents, ANA598, a non- nucleoside polymerase inhibitor and ANA773, an oral TLR7 agonist prodrug. The Company is also developing ANA773 for the treatment of cancer.

Safe Harbor Statement

Statements in this press release that are not strictly historical in nature constitute "forward-looking statements." Such statements include, but are not limited to, references to the expected timing and planned development activities for ANA598 and ANA773, including the trial design, occurrence, timing, and pace of future clinical trials, the timing for obtaining viral load data and expectations regarding such data, as well as the anticipated future clinical benefits of ANA598 and ANA773. Such forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause Anadys' actual results to be materially different from historical results or from any results expressed or implied by such forward- looking statements. For example, the results of preclinical studies and early clinical trials may not be predictive of future results, and Anadys cannot provide any assurances that ANA598 or ANA773 will not have unforeseen safety issues, will have favorable results in future clinical trials or will receive regulatory approval. In addition, Anadys' results may be affected by competition from other biotechnology and pharmaceutical companies, its effectiveness at managing its financial resources, its ability to enter into collaborations around its product candidates, its ability to successfully develop and market products, difficulties or delays in its preclinical studies or clinical t
'/>"/>

SOURCE Anadys Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
2. Anadys Pharmaceuticals to Report Third Quarter 2007 Financial Results
3. Anadys Pharmaceuticals to Present at the Acumen BioFin Rodman & Renshaw Healthcare Conference
4. Anadys Pharmaceuticals Reports Third Quarter 2007 Financial Results and Operational Highlights
5. Anadys Pharmaceuticals to Present at the Piper Jaffray Health Care Conference
6. Anadys Pharmaceuticals to Present at the JPMorgan Healthcare Conference
7. Anadys Pharmaceuticals to Present at the BIO CEO & Investor Conference
8. Anadys Pharmaceuticals to Report Fourth Quarter and Year-End 2007 Financial Results
9. Anadys Pharmaceuticals to Present at the Susquehanna SIGnificant Options in Healthcare Conference
10. Anadys Pharmaceuticals Commences Phase I Clinical Trial of ANA773 in Cancer Patients
11. Anadys Pharmaceuticals to Present at the Cowen and Company Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... OXFORD, England and SAN JOSE, California ... an international biotechnology company developing antibody-drug conjugates for cancer, today ... its Board of Directors. Dr Reynolds has over 20 years, ... Chief Medical Officer at Seattle Genetics. "I am ...
(Date:1/15/2014)... England , January 15, 2014 A ... win races on the Formula 1 track could help to ... McLaren Applied Technologies (MAT), Stowhealth (a GP surgery based in ... by healthcare provider Simplyhealth. Telemetry technology, which is ...
(Date:1/15/2014)... The Microcompetition with Foreign DNA theory explains how latent viruses ... is the Epstein Barr Virus (EBV), and one of these ... chronic inflammatory disease that destroys the body’s joints. As predicted ... high concentrations of EBV DNA in their bodies (1). ...
(Date:1/15/2014)... CA (PRWEB) January 15, 2014 ... research solutions, today announced that Lupin Limited, one of ... Freeslate’s CM Protégé PharmD System for high ... Mumbai, India, is focused on a wide range of ...
Breaking Biology Technology:Oxford BioTherapeutics Appoints Thomas C Reynolds MD, PhD to its Board of Directors 2Oxford BioTherapeutics Appoints Thomas C Reynolds MD, PhD to its Board of Directors 3Formula 1 Technology Tackles Obesity in Unique Healthcare Partnership 2Formula 1 Technology Tackles Obesity in Unique Healthcare Partnership 3Formula 1 Technology Tackles Obesity in Unique Healthcare Partnership 4Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 2Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 3Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 2Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 3
... Eden Prairie-,based molecular diagnostics service and technology company, announced ... CFO, and Elizabeth A. Skinner,as VP - Legal, Quality ... Edwin Watts Golf, and has previously,served as VP of ... Signal,Aerospace, and corporate controller of NCR Corporation. He holds ...
... Inc. (Amex:,ADL), headquartered in Tustin, California, with ... its wholly owned subsidiary Jade,Pharmaceutical Inc. (JPI), ... the development, manufacture and marketing of proprietary,pharmaceutical ... JPI has,signed an agreement with Heze Mudan ...
... surface addresses key factors in the prevention and treatment ... pressure ulcers to enhance patient safety and comfort, ... HB ) today announced its Hill-Rom subsidiary has,introduced a ... patients with pressure ulcers. The Hill-Rom(R) E700 Wound Surface ...
Cached Biology Technology:Access Genetics Announces New Executive Appointments 2AMDL Expands Drug Distribution in China With Additional Agreement, Valued at $2.3 Million Annually 2Hill-Rom Introduces New Wound Therapy Surface With Innovative Safety and Treatment Features 2Hill-Rom Introduces New Wound Therapy Surface With Innovative Safety and Treatment Features 3Hill-Rom Introduces New Wound Therapy Surface With Innovative Safety and Treatment Features 4Hill-Rom Introduces New Wound Therapy Surface With Innovative Safety and Treatment Features 5
(Date:4/22/2014)... begins a trip to Asia to coordinate with ... Pacific, officials at the Office of Naval Research ... Partnership (APTEP) as an example of strong and ... allies in the region. , The APTEP program, ... region, supports the development of alternative energy technologies. ...
(Date:4/22/2014)... available in French . ... sequencing of the complete genome and subsequent phylogenetic analysis ... clade (variant) that is distinct from strains previously identified ... Epidemiological investigations also linked the laboratory confirmed cases with ... , Ebola virus is a lethal, highly contagious virus ...
(Date:4/22/2014)... studies have shown that exposure to environmental ... region, thus improving learning and memory. Previous ... exist predominantly in the superficial layer of ... as guinea pigs, and these neurons exhibit ... under physiological conditions. Whether environmental enrichment has ...
Breaking Biology News(10 mins):Full power: Alternative energy partnerships flourish in Asia 2Full power: Alternative energy partnerships flourish in Asia 3Inserm and the Institut Pasteur identify a new variant of Ebola virus in Guinea 2
... Mars or any planet, there is much more than the ... cycles as a reference point, elements like nitrogen, iron and ... in studies published in February,s open-access Special Issue of Frontiers ... together to support an extraordinary diversity of life. ...
... SAN ANTONIO (Feb. 2, 2011) Obesity among ... of obese mothers are themselves predisposed to obesity, society ... people to continue through future generations. In ... San Antonio obstetrics researchers are studying the question: If ...
... , The same properties that make engineered nanoparticles attractive ... stabile, and water-solublealso cause concern about their long-term impacts ... the tendency for nanoparticles to clump together in solution, ... clusters may be key to whether or not they ...
Cached Biology News:Earth's life support systems discussed in an open-access special issue 2Losing body fat before pregnancy can be beneficial for the baby 2NIST technique controls sizes of nanoparticle clusters for EHS studies 2
Physical Form: powder Color: white Removes FLAG peptide from N-terminal and Met-N-terminal fusion proteins. Supplied with optimized enterokinase buffer....
This antibody detects ubiquitinated proteins on SDS-PAGE immunoblots. It does not detect free ubiquitin....
... The Jouan B4i ventilated and BR4i refrigerated multifunction ... low speed operation at a low sound level ... certified for biocontainment. Their AUTO-LOCK rotor exchange system ... ready for use within seconds. Instant ...
... BR4i refrigerated multifunction centrifuges are equally capable of ... low sound level with a large range of ... rotor exchange system without tools ensures that the ... Instant rotor exchange (5 sec.) ...
Biology Products: